Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K, Horita N, Kaneko A, Tagami Y, Fukuda N, Matsumoto H, Namkoong H, Fujiwara Y, Minegishi K, Fukumoto T, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Somekawa K, et al. Among authors: horita n. Ther Adv Med Oncol. 2022 Feb 11;14:17588359211058393. doi: 10.1177/17588359211058393. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173819 Free PMC article.
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD. Fujiwara Y, et al. Among authors: horita n. Cancer Immunol Immunother. 2022 Dec;71(12):2837-2848. doi: 10.1007/s00262-022-03203-7. Epub 2022 Apr 26. Cancer Immunol Immunother. 2022. PMID: 35471602 Free PMC article. Review.
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H, Somekawa K, Horita N, Ueda S, Kaneko M, Kaneko A, Fukuda N, Izawa A, Kamimaki C, Tanaka K, Murohashi K, Fuji H, Tagami Y, Aoki A, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Matsumoto H, et al. Among authors: horita n. Ther Adv Med Oncol. 2023 Sep 13;15:17588359231198453. doi: 10.1177/17588359231198453. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37720498 Free PMC article. Review.
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
Priantti JN, Fujiwara Y, Aquino de Moraes FC, Michelon I, Castro C, Leighl NB, Cavalcante L, Addeo A, Bar J, Horita N, Cortellini A, Nassar AH, Vilbert M, Naqash AR. Priantti JN, et al. Among authors: horita n. JCO Precis Oncol. 2024 Nov;8:e2400331. doi: 10.1200/PO.24.00331. Epub 2024 Nov 22. JCO Precis Oncol. 2024. PMID: 39576954
362 results